Optellum and Volpara Health Announce Agreement for Lung & Breast Cancer Care

Collaboration brings together leading lung and breast imaging expertise to advance AI-driven cancer detection and early intervention.

HOUSTON, March 4, 2025 /PRNewswire/ — Optellum, the leader in AI-enabled lung cancer diagnosis, today announced it has entered a strategic agreement with Volpara Health, a Lunit company and a global leader in software for the early detection of cancer, designed to expand a patient’s picture of cancer risk. This agreement will enable Volpara customers, including over 3,500 facilities in the U.S. that rely on Volpara software for early detection, to gain access to Optellum’s Virtual Nodule Clinic software that identifies the probability that a lung nodule is cancerous.

With FDA clearance, comprehensive reimbursement, and a proven track record, Optellum helps providers identify more cancers at an earlier stage and make well-informed decisions on patient management and care pathways. The company’s Lung Cancer Prediction AI^® complements Volpara’s tools that quantify breast tissue density, optimize mammography workflows, and refine risk assessments—ensuring clinicians can adopt a truly personalized approach to cancer diagnosis.

“Every patient deserves the earliest possible diagnosis, and by coming together with Volpara, more clinicians will have a more complete picture of their patients’ health,” said Johnathan Watkins, CEO of Optellum. “In the field of cancer screening and diagnostics, AI-driven imaging and risk assessment tools will continue to impact the approach to early detection and treatment planning.”

“Getting more evidence-based, early detection technologies into the hands of clinicians will allow for more accurate detection and ultimately save more families from cancer,” said Teri Thomas, CEO of Volpara Health. “We are committed to being objective consultants to the institutions we serve and bringing them the best AI tools with the potential to translate into more life-saving advancements for their patients.”

With the capabilities to quantify patient risk for both breast and lung cancer, clinicians will have advanced evaluation metrics to prioritize patients and enable precision medicine.

About Optellum

Optellum is a commercial-stage lung health company providing AI-powered decision-support software that assists physicians in early diagnosis and optimal treatment for patients. The company was founded so that every lung disease patient could be diagnosed and treated at the earliest possible stage, when the probability of better health outcomes is highest.

Optellum is the leader in AI-enabled lung cancer diagnosis, and the first and only MedTech company to have attained FDA 510(k) clearance, Medicare reimbursement in the USA, as well as CE-MDR in the EU and UKCA in the UK for its software platform, Virtual Nodule Clinic.

Optellum is located at the Oxford Centre for Innovation in Oxford, United Kingdom and in the US at the Texas Medical Center in Houston, Texas.  For more information, visit their website at www.optellum.com. 

About Volpara Health 

Volpara Health is on a mission to save families from cancer with AI-powered software that helps healthcare providers better understand cancer risk, guide personalized care decisions, and recommend additional imaging and interventions. Used in over 3,500 facilities by more than 9,500 technologists worldwide. Volpara’s software impacts nearly 18M patients, supports over 3.6M annual cancer risk assessments, and integrates seamlessly with electronic health records and imaging systems. Volpara helps radiologists quantify dense breast tissue with precision and technologists produce mammograms with optimal positioning, compression, and dose. Volpara software also streamlines operations to ease compliance and accreditation. Volpara, a Lunit company, is headquartered in Wellington, New Zealand, and has an office in Seattle. Volpara is the trusted partner of leading healthcare institutions globally. For more information, visit www.volparahealth.com.

Optellum Media Contact:   

James Hounsell
Evolene Ltd.
james.hounsell@evolene.co.uk 

Volpara Media Contact:   

Andrew Thompson-Young
Clarity Quest
Andrew@Clarityqst.com
877-887-7611

View original content to download multimedia:https://www.prnewswire.com/news-releases/optellum-and-volpara-health-announce-agreement-for-lung–breast-cancer-care-302391589.html

SOURCE Optellum